Literature DB >> 28461308

Severe eosinophilic asthma: a roadmap to consensus.

Roland Buhl1, Marc Humbert2, Leif Bjermer3, Pascal Chanez4, Liam G Heaney5, Ian Pavord6, Santiago Quirce7, Johann C Virchow8, Stephen Holgate9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28461308     DOI： 10.1183/13993003.00634-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  32 in total

Review 1.  Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma.

Authors:  Leyla Pur Özyiğit; Ayşe Bilge Öztürk; Sevim Bavbek
Journal:  Turk Thorac J       Date:  2020-01-01

2.  Unmet Needs in Severe Asthma Subtyping and Precision Medicine Trials. Bridging Clinical and Patient Perspectives.

Authors:  Salman Siddiqui; Loren C Denlinger; Stephen J Fowler; Praveen Akuthota; Dominick E Shaw; Liam G Heaney; Louise Brown; Mario Castro; Tonya A Winders; Monica Kraft; Scott Wagers; Michael C Peters; Ian D Pavord; Samantha Walker; Nizar N Jarjour
Journal:  Am J Respir Crit Care Med       Date:  2019-04-01       Impact factor: 21.405

Review 3.  Overlapping Effects of New Monoclonal Antibodies for Severe Asthma.

Authors:  Christian Domingo
Journal:  Drugs       Date:  2017-10       Impact factor: 9.546

Review 4.  Immune Modulation in Asthma: Current Concepts and Future Strategies.

Authors:  Marek Lommatzsch
Journal:  Respiration       Date:  2020-06-08       Impact factor: 3.580

5.  Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study.

Authors:  Shoko Isoyama; Nobuhisa Ishikawa; Kosuke Hamai; Mirai Matsumura; Hiroki Kobayashi; Akio Nomura; Sayaka Ueno; Takuya Tanimoto; Hiroyuki Maeda; Hiroshi Iwamoto; Noboru Hattori
Journal:  Intern Med       Date:  2022-06-01       Impact factor: 1.282

Review 6.  Type 2 immunity-driven diseases: Towards a multidisciplinary approach.

Authors:  Dorian Hassoun; Olivier Malard; Sébastien Barbarot; Antoine Magnan; Luc Colas
Journal:  Clin Exp Allergy       Date:  2021-10-15       Impact factor: 5.401

Review 7.  Add-on Therapy for Symptomatic Asthma despite Long-Acting Beta-Agonists/Inhaled Corticosteroid.

Authors:  Michael Dreher; Tobias Müller
Journal:  Tuberc Respir Dis (Seoul)       Date:  2017-12-13

Review 8.  Clinical Research Needs for the Management of Chronic Rhinosinusitis with Nasal Polyps in the New Era of Biologics: A National Institute of Allergy and Infectious Diseases Workshop.

Authors:  Robert Naclerio; Fuad Baroody; Claus Bachert; Benjamin Bleier; Larry Borish; Erica Brittain; Geoffrey Chupp; Anat Fisher; Wytske Fokkens; Philippe Gevaert; David Kennedy; Jean Kim; Tanya M Laidlaw; Jake J Lee; Jay F Piccirillo; Jayant M Pinto; Lauren T Roland; Robert P Schleimer; Rodney J Schlosser; Julie M Schwaninger; Timothy L Smith; Bruce K Tan; Ming Tan; Elina Toskala; Sally Wenzel; Alkis Togias
Journal:  J Allergy Clin Immunol Pract       Date:  2020-03-04

9.  Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme.

Authors:  Camille Taillé; Pascal Chanez; Gilles Devouassoux; Alain Didier; Christophe Pison; Gilles Garcia; Jeremy Charriot; Stéphane Bouée; Alina Gruber; Celine Pribil; Arnaud Bourdin; Marc Humbert
Journal:  Eur Respir J       Date:  2020-06-25       Impact factor: 16.671

Review 10.  Distinct functions of eosinophils in severe asthma with type 2 phenotype: clinical implications.

Authors:  Youngwoo Choi; Soyoon Sim; Hae-Sim Park
Journal:  Korean J Intern Med       Date:  2020-05-29       Impact factor: 2.884
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.